Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac (Q28192346)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 15 February 2002)

Language	Label	Description	Also known as
English	Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac	scientific article (publication date: 15 February 2002)

Statements

scholarly article

0 references

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

thromboembolism

1 reference

based on heuristic

inferred from title

author name string

William B White

1

0 references

Gerald Faich

2

0 references

Andrew Whelton

3

0 references

Clement Maurath

4

0 references

Nancy J Ridge

5

0 references

Kenneth M Verburg

6

0 references

G Steven Geis

7

0 references

James B Lefkowith

8

0 references

language of work or name

0 references

publication date

15 February 2002

0 references

American Journal of Cardiology

0 references

89

0 references

4

0 references

425-30

0 references

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902265-2

7 January 2021

Identifiers

10.1016/S0002-9149(01)02265-2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28192346&oldid=2091947114"